仙琚制药：阿更葡糖钠注射液尚在评审阶段

Group 1 - The core viewpoint of the article is that Xianju Pharmaceutical (002332) has engaged in preliminary commercialization preparations for the drug Ageng Glucosamine Sodium Injection, but the financial impact on current operations is expected to be minor due to uncertainties in approval and market access [1][1][1] Group 2 - The company has signed various agreements related to the product, but the specific financial amounts have not been disclosed, citing potential commercial confidentiality [1][1] - The product is currently under review, and there are uncertainties regarding its approval and the timeline for market entry, as well as negotiations with health insurance [1][1][1]